Drugs

$Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor$

Photo from Paolo Tarantino/LinkedIn

Apr 8, 2024, 03:54

Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor

Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“Trastuzumab deruxtecan (T-DXd) is now FDA approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) solid tumor, making it the first agnostic ADC. Unlikely to be the last. First priority: ensuring that HER2 testing is expanded across cancer types. Exciting times!”

Read further.
Source: Paolo Tarantino/LinkedIn

agnostic ADC breast oncology cancer Dana-Farber Cancer Institute FDA FDA approved HER2 OncoDaily Oncology Paolo Tarantino Trastuzumab Deruxtecan (T-DXd)

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage